Early or Late Gefitinib, Which is Better for Survival?: Retrospective Analysis of 228 Korean Patients with Advanced or Metastatic NSCLC.
10.12701/yujm.2011.28.1.31
- Author:
Dong Gun KIM
1
;
Min Kyoung KIM
;
Sung Hwa BAE
;
Sung Ae KOH
;
Sung Woo PARK
;
Hyun Je KIM
;
Myung Jin KIM
;
Hyo Jin JANG
;
Kyung Hee LEE
;
Kwan Ho LEE
;
Jin Hong CHUNG
;
Kyung Chul SHIN
;
Hun Mo RYOO
;
Myung Soo HYUN
Author Information
1. Division of Oncology, Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea. kmk21c@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
Tyrosine kinase inhibitor;
Gefitinib;
Non-small cell lung cancer
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Disease-Free Survival;
Humans;
Phosphotransferases;
Quinazolines;
Retrospective Studies;
Smoke
- From:Yeungnam University Journal of Medicine
2011;28(1):31-44
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The optimal timing of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI) in NSCLC patients has not yet been determined. METHODS: We separated 228 patients with advanced/metastatic NSCLC treated with gefitinib into an early gefitinib group (patients who received gefitinib as first- or second-line treatment) and a delayed gefitinib group (patients who received gefitinib as third or fourth-line treatment) and attempted to determine whether the timing of gefitinib treatment affected clinical outcomes. RESULTS: Median overall survival (OS), progression free survival (PFS), and median OS from first-line treatment of advanced/metastatic disease (OSt) for 111 patients in the early gefitinib group were 6.2 months, 3.3 months, and 11.6 months. However, median OS, PFS, and OSt for 84 patients in the delayed gefitinib group were 7.8 months, 2.3 months, and 22.7 months. No differences in OS and PFS were observed between the 2 groups. However, OSt was significantly longer in the delayed gefitnib group. Timing of gefitinib therapy was one of the independent predictors of OSt. Hb > or = 10 g/dl, and having never smoked, and ECOG performance status < or =1 were independent predictors of better PFS. CONCLUSION: Deferral of gefitinib therapy in patients with advanced or metastatic NSCLC may be preferable if they are able to tolerate chemotherapy.
